BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 19028987)

  • 1. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
    Williams RT; Sherr CJ
    Cold Spring Harb Symp Quant Biol; 2008; 73():461-7. PubMed ID: 19028987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc.
    Haviernik P; Schmidt M; Hu X; Wolff L
    Oncogene; 2003 Mar; 22(11):1600-10. PubMed ID: 12642863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model mice for BCR/ABL-positive leukemias.
    Honda H; Hirai H
    Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
    Williams RT; Sherr CJ
    Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.
    Young FM; Campbell A; Emo KL; Jansson J; Wang PY; Jordan CT; Mullen CA
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):622-30. PubMed ID: 18489987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One INK4 gene and no ARF at the Fugu equivalent of the human INK4A/ARF/INK4B tumour suppressor locus.
    Gilley J; Fried M
    Oncogene; 2001 Nov; 20(50):7447-52. PubMed ID: 11704876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rearrangement and expression of bcr-abl genes in CML and ALL].
    Kunieda Y; Okabe M
    Rinsho Ketsueki; 1991 Jun; 32(6):623-8. PubMed ID: 1890738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of BCR/ABL fusion proteins on the course of Ph leukemias.
    Telegeev GD; Dubrovska AN; Dybkov MV; Maliuta SS
    Acta Biochim Pol; 2004; 51(3):845-9. PubMed ID: 15448745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
    Chen ZX; Kaeda J; Saunders S; Goldman JM
    Chin Med J (Engl); 2004 Jul; 117(7):968-71. PubMed ID: 15265366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
    Williams RT; Roussel MF; Sherr CJ
    Proc Natl Acad Sci U S A; 2006 Apr; 103(17):6688-93. PubMed ID: 16618932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Getting to the stem of chronic myeloid leukaemia.
    Savona M; Talpaz M
    Nat Rev Cancer; 2008 May; 8(5):341-50. PubMed ID: 18385684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of p53 in leukemogenesis of chronic myeloid leukemia.
    Lanza F; Bi S
    Stem Cells; 1995 Jul; 13(4):445-52. PubMed ID: 7549904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias.
    Chim CS; Wong AS; Kwong YL
    Ann Hematol; 2003 Dec; 82(12):738-42. PubMed ID: 14513284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
    Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG
    Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
    Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
    Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.